Official NIH NLM MEDLINE / PubMed Citation • PMID: 42441396
Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial.
JAMA
Verbatim Formal Study Abstract
Of the 327 randomized participants (mean age, 73.4 years; 201 [61.5%] females), 259 (87 receiving ceperognastat 0.75 mg, 86 receiving ceperognastat 3 mg, and 86 receiving placebo) with low to medium baseline tau levels were included in the primary outcome population (mean age, 74